首页> 美国卫生研究院文献>Journal of the International AIDS Society >No significant association between patient self-reported non-adherence to antiretrovirals and HIV-tropism: a preliminary analysis
【2h】

No significant association between patient self-reported non-adherence to antiretrovirals and HIV-tropism: a preliminary analysis

机译:患者自我报告对抗逆转录病毒药物的依从性与HIV偏爱性之间无显着关联:初步分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nonadherence to antiretroviral therapy (ART) may cause virologic failure and disease progression has been associated with switch of viral coreceptor usage from CCR5 to CXCR4. We aimed to assess the association between patient-reported non-adherence and HIV tropism. This is a cross-sectional analysis. HIV-tropism was performed within routine clinical practice either at start of ART or at virological failure. Adherence questionnaire includes: how many times ART has been taken during the last month, missed doses in the last week, timing deviation, refill interruption, drug holidays. Demographics, epidemiological data, HIV and ART history, CD4 and HIVRNA were collected. To assess co-receptor tropism, env V3 genotyping from viremic plasma HIVRNA was performed. For the analysis, dual/mixed viruses were considered as X4. We included 102 individuals: 76% males; median age 42 y (IQR, 37–46); transmission was heterosexual 37%, homosexual 31%, intravenous drug use 29%. Median nadir of CD4 154/mmc (IQR, 53–274), median zenith of HIVRNA 5.26 (4.72–5.70), 46% had AIDS. 124 tropism tests were: 78% R5, 17% X4, 5% dual/mixed. In cases with previous ART, mono/dual ART was found in 26%, median number of regimens was 5 (IQR, 2–10), median time on triple-ART was 54 months (IQR, 0–123) with median time of HIVRNA <50 c/ml of 16 months (IQR, 6.5–34.9). At HIV-tropism, median CD4 and HIV RNA were 321/mmc (IQR, 210–436) and 2.65 (IQR, 2.65–4.91), respectively. Median time between adherence questionnaire and HIV-tropism was 68 days (IQR, 23–116). At adherence questionnaire, median percentage of ART taken during the last month was 100% (IQR, 90–100), 39% reported missed doses in the last week, 40% timing deviation, 7% refill interruption, 17% drug holidays. At univariate analysis, no statistically significant association between non-adherence and dual/mixed-X4 viruses was found (p>0.1). Also gender, age, HIV transmission, AIDS, CD4 nadir, HIVRNA zenith, mono/dual ART, and number of ART regimens were not associated with type of tropism. Only longer time with undetectable HIVRNA before tropism test showed a lower probability of dual/mixed-X4 viruses (OR for each month 0.95; 95% CI 0.90–1.00; p=0.06). No significant association between adherence and HIV-tropism was found in this preliminary analysis. It is possible that patient self-reported adherence is not able to capture nonadherence behaviors that underlie more pronounced viral replication which may be necessary for tropism switch.
机译:不坚持抗逆转录病毒疗法(ART)可能会导致病毒学衰竭,疾病进展与病毒共受体的使用从CCR5切换到CXCR4有关。我们旨在评估患者报告的不依从性与HIV嗜性之间的关联。这是横截面分析。在开始抗逆转录病毒治疗或病毒学失败时,应在常规临床实践中进行HIV定向治疗。依从性调查表包括:上个月进行了多少次抗逆转录病毒治疗,上周错过了剂量,时间偏差,补药中断,禁药期。收集了人口统计学,流行病学数据,HIV和ART历史,CD4和HIVRNA。为了评估共受体向性,从病毒血症血浆HIVRNA进行env V3基因分型。为了进行分析,将双重/混合病毒视为X4。我们纳入了102个人:76%为男性;中位年龄42岁(IQR,37-46);传播为异性恋37%,同性恋31%,静脉吸毒29%。 CD4 154 / mmc(IQR,53–274)的中位数最低点,HIVRNA的中位数最高值为5.26(4.72–5.70),其中46%患有艾滋病。 124个向性测试为:78%R5、17%X4、5%双重/混合。在先前曾接受过抗逆转录病毒治疗的患者中,单/双重抗逆转录病毒治疗的发生率为26%,中位治疗方案数为5(IQR,2–10),三重抗病毒治疗的中位时间为54个月(IQR,0–123),中位时间为16个月内HIVRNA <50 c / ml(IQR,6.5-34.9)。在HIV嗜性方面,中位数CD4和HIV RNA分别为321 / mmc(IQR,210-436)和2.65(IQR,2.65-4.91)。依从性问卷调查和HIV偏爱之间的中位时间为68天(IQR,23–116)。在依从性调查表中,上个月接受ART的中位数百分比为100%(IQR,90-100),上周报告的错过剂量为39%,时间偏差为40%,加药中断为7%,药物假期为17%。在单变量分析中,未发现非粘附性病毒与双重/混合X4病毒之间存在统计学上的显着关联(p> 0.1)。同样,性别,年龄,HIV传播,艾滋病,CD4最低点,HIVRNA天顶,单/双抗逆转录病毒治疗以及抗逆转录病毒治疗方案的数量与嗜性类型无关。在向向性测试之前,只有较长时间检测不到HIVRNA才显示双重/混合X4病毒的可能性较低(每月OR为0.95; 95%CI为0.90–1.00; p = 0.06)。在此初步分析中,依从性与HIV趋向性之间未发现明显关联。患者自我报告的依从性可能无法捕获非依从性行为,这些行为是更显着的病毒复制的基础,这可能是向性转换所必需的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号